Individuals who reside in louder regions are more at risk of developing Alzheimer’s, new report shows.
A sound-level spike of only 10 decibels raised the risk by 30 percent. That is the gap between breathing and whispering. It also culminated in 36 percent greater chances of moderate cognitive disability, including memory and reasoning ability, scientists said.
Twenty Veterans with Alzheimer’s disease and apathy took part in a pilot study. Half received repetitive transcranial magnetic stimulation (rTMS), a type of brain stimulation. The others received sham stimulation, basically a placebo.
Through patient and caregiver interviews, the VA team documented “significantly greater improvement” in apathy levels in those who received brain stimulation compared with the control group. The positive effects continued up to three months.
Besides improvements in apathy, the researchers also noted “significantly greater improvement” in memory, attention, and cognition in the rTMS patients compared with the sham treatment group.
The writer of the post in our link for today developed an approach that allowed us to activate the neurons that store memory information, referred to as memory engrams, through optogenetics—that is, introducing a gene that is light sensitive into the memory engram cells of “Alzheimer’s” mice, then delivering blue light pulses to activate them—and measuring memory recall strength directly. To our surprise, we found comparable numbers of engram cells in normal healthy animals and Alzheimer’s animals, suggesting that the initial memory storage process is intact. Targeting the recall process in Alzheimer’s animals led to an improvement in their memory, which reached the performance level of normal animals.
Supporting demented patients, who are mostly unresponsive, without making demands or asking a question and regarding them as valuable human beings unexpectedly improve their memory performance around the time of death.
Swiss biopharma AC Immune has made targeting Alzheimer’s disease, the leading form of dementia, a top priority. The company’s numerous candidates and platforms target several different proteins and pathways thought to have a central role in Alzheimer’s pathology. 2020 has brought mixed news for AC Immune. In July, the company announced that their candidate tau vaccine, ACI-35.030, had shown “encouraging” safety data at a lower dose and was to be progressed to a higher-dose group. However, September brought the disappointing news that their anti-tau antibody, semorinemab, did not meet its primary efficacy endpoints in a Phase 2 trial. To discuss AC Immune’s work, Technology Networks spoke to CEO Prof. Andrea Pfeifer.
A study released Wednesday by USC researchers found that older women who live in areas with high levels of air pollution may have more Alzheimer’s-like brain shrinkage than those who live in places with cleaner air.
Government health advisers sharply criticized a closely watched Alzheimer’s drug on Friday, concluding there wasn’t enough evidence that the experimental drug slowed the brain-destroying disease.
The panel of outside experts for the Food and Drug Administration agreed that a pivotal study in patients failed to show “strong evidence” that the drug worked. The experts warned of multiple “red flags” with the data, which did not initially show any benefit until another analysis with later results.
The first blood test designed to assist physicians in determining whether a patient has Alzheimer’s disease is now available in most US states, the company C2N Diagnostics announced October 29. The test measures biomarkers that frequently reflect the presence of amyloid plaques in the brain—a hallmark of Alzheimer’s—as well as the presence of a gene variant that increases the risk of the disease.
An artificial intelligence (AI) tool was able to accurately predict Alzheimer’s disease almost eight years before a person was diagnosed, according to a study recently published in the journal EClinicalMedicine, and researchers say the tool could help providers to identify patients in early stages of the disease.
Where lots of studies have been halted due to the pandemic, the large study at the the Institute for Memory Impairments and Neurological Disorders at the University of California, Irvine is moving forward cautiously.
Read the article in our link for today to learn about how they assure the safety of the participants in the study.
Immunotherapy is the prevention or treatment of disease with drugs that stimulate an immune response. Scientists are looking for a cure to Alzheimer’s disease that boosts our immune systems. Administering drugs to elicit an immune response works in a similar way to a vaccine and pharmaceutical companies are placing bets on immunotherapy to target Alzheimer’s disease.
The clinical guidelines related to the primary prevention of Alzheimer’s disease (AD) have focused on the management of vascular risk factors. However, the link between vascular risk factors and AD in older adults remains unclear. This study aimed to determine the association between vascular risk factors and subsequent AD in 178,586 older adults (age ≥ 65 years).
Why are women diagnosed more with Alzheimer’s than men?
One study found menopause, which reduces estrogen levels in a women’s body, may be to blame. Scientists scanned the brains of women and men and found declines in estrogen were involved in Alzheimer’s abnormalities.
Another recent report found women with more belly fat had a higher risk for dementia than men with the same issue. Specifically, women with a higher waist circumference had a 39% increased risk of dementia in 15 years.
And researchers recently performed brain scans on more than 1,000 older adults and found women metabolized sugar better, which may help them compensate for dementia damage better causing a delayed diagnosis.
The first infusion of an investigational drug that aims to delay or help to prevent the earliest memory loss due to Alzheimer’s disease took place in September at Butler Hospital in Providence, R.I., researchers announced.
A new study from a Penn researcher adds to evidence that a class of antidepressant drugs known as SSRIs may reduce production of a key protein found in the brains of people with Alzheimer’s disease. This is evidence, she said, that the drugs could someday be part of a cocktail used to prevent or delay this form of dementia.
A team led by Dr Laura Ferraiuolo of The University of Sheffield have found that AI could be used to assess and monitor potential patients. Specifically, machines could be programmed to recognise Alzheimer’s by looking at an image of a patient’s brain, as well as assessing their movements and speech to determine if they are likely to be suffering from the condition before symptoms progress.
Researchers compared the navigation performance of 202 volunteers without genetic Alzheimer’s risk and 65 volunteers with increased genetic risk. The latter had a specific expression of the gene for apolipoprotein E, the APOE-ε4 allele.
An interesting development is that apparently an experimental drug, aimed to help people with Alzheimer’s, could play a role in helping children with certain types of Autims. Read the full story in our link for today.
Clinical trials of Alzheimer’s medicines have failed frequently but now researchers believe that this may have been caused by the drugs given too late. So if they could just develop a test that would detect Alzheimer’s earlier, it would make the drugs that have failed for use later in the process, so much more productive.